Focus on IL-6 Inhibitors for Optimizing Multimodal Management of RA
A Real World Approach to Unmet Needs, Patient-Centric Care, Special Populations, and Sequencing Biologic Therapies for Rheumatoid Arthritis (RA)
A Real World Approach to Unmet Needs, Patient-Centric Care, Special Populations, and Sequencing Biologic Therapies for Rheumatoid Arthritis (RA)
Course Videos
Video
When a suboptimal clinical response has been encountered with TNF or interleukins antagonists, what other biologic strategies have been shown to be effective in clinical trials? How are these sequencing decisions made and where might an ...
Video
How good are the disease outcome metrics recommended by ACR and what are their limitations?
How good are the disease outcome metrics recommended by ACR and what are their limitations?
Video
Have advantages been documented for IL-6 inhibitors that are fully human such as sarilumab?
Have advantages been documented for IL-6 inhibitors that are fully human such as sarilumab?
Video
What side effects are you most concerned about when using TNFIs or IL-6 inhibitors?
What side effects are you most concerned about when using TNFIs or IL-6 inhibitors?
Video
Under what circumstances do you use monotherapy with methotrexate and when do you use combination therapy and intensify treatment with a biologic agent?
Video
What triggers do you use in your RA patients to begin a DMARD or biologic agent?
What triggers do you use in your RA patients to begin a DMARD or biologic agent?
Video
What are the possible advantages of targeting the IL-6 cytokine system? Please discuss as it relates to stabilization of chronic disease, effects of global symptom scores, and ability to mitigate rapidly progressive RA.
Video
When a suboptimal clinical response has been encountered with TNFIs or interleukins antagonists, what other biologic strategies have been shown to be effective in clinical trials? How are these sequencing decisions made and where might an IL-6 inhibitor fit?
Video
In what patient subsets (RA biomarker subsets, obese, undifferentiated RA, high risk RA, poor responders, etc.) do IL-6 inhibitors appear to be most effective? Do they seem to optimize outcomes when they are used earlier in the natural history of the disease?
Video
Is it your view that the effectiveness and side effect profiles of different IL-6 inhibitors — established and soon-to-market — will reflect a class effect, or do you feel they will be clinically differentiated?
Video
In general, how rapid is the onset of action of IL-6 inhibitors and can these agents be used as monotherapy?
Video
What evidence and clinical guidance is offered by trials evaluating the role, safety, and efficacy of IL-6 targeting agents in the setting of RA?